X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (272) 272
temsirolimus (251) 251
index medicus (246) 246
oncology (236) 236
sirolimus - analogs & derivatives (161) 161
mammalian target (148) 148
cancer (146) 146
everolimus (118) 118
female (115) 115
rapamycin (115) 115
mtor (108) 108
antineoplastic agents - therapeutic use (97) 97
temsirolimus cci-779 (94) 94
male (92) 92
middle aged (87) 87
sirolimus - therapeutic use (87) 87
phase-ii trial (83) 83
aged (73) 73
cci-779 (73) 73
medicine & public health (73) 73
tor serine-threonine kinases - antagonists & inhibitors (73) 73
animals (72) 72
sirolimus - pharmacology (70) 70
research (69) 69
interferon-alpha (68) 68
pharmacology & pharmacy (68) 68
adult (65) 65
care and treatment (65) 65
renal-cell carcinoma (62) 62
carcinoma, renal cell - drug therapy (61) 61
tor serine-threonine kinases (61) 61
kidney neoplasms - drug therapy (60) 60
sirolimus - adverse effects (60) 60
sirolimus - administration & dosage (59) 59
drug therapy (58) 58
phase-ii (58) 58
neoplasms - drug therapy (56) 56
protein kinase inhibitors - therapeutic use (53) 53
mtor inhibitor (52) 52
antineoplastic agents (50) 50
renal cell carcinoma (49) 49
antimitotic agents (47) 47
treatment outcome (47) 47
sorafenib (45) 45
bevacizumab (44) 44
carcinoma, renal cell (44) 44
antineoplastic agents - adverse effects (43) 43
sunitinib (43) 43
chemotherapy (42) 42
clinical trials as topic (41) 41
antineoplastic agents - pharmacology (39) 39
antineoplastic combined chemotherapy protocols - therapeutic use (39) 39
article (39) 39
signal transduction - drug effects (38) 38
metastasis (37) 37
cell line, tumor (35) 35
health aspects (35) 35
sirolimus (35) 35
clinical trials (34) 34
hematology, oncology and palliative medicine (34) 34
pharmacology/toxicology (34) 34
breast-cancer (33) 33
endothelial growth-factor (33) 33
mtor inhibitors (33) 33
tor serine-threonine kinases - metabolism (33) 33
pathway (32) 32
signal transduction (32) 32
therapy (32) 32
tumors (32) 32
dosage and administration (30) 30
mammalian target of rapamycin (30) 30
cancer research (29) 29
growth (29) 29
inhibitor (29) 29
protein kinases - metabolism (29) 29
mice (27) 27
single-agent temsirolimus (27) 27
trial (27) 27
aged, 80 and over (26) 26
hematology (26) 26
pharmacokinetics (26) 26
sirolimus - pharmacokinetics (26) 26
kidney neoplasms - pathology (25) 25
targeted therapy (25) 25
antineoplastic combined chemotherapy protocols - adverse effects (24) 24
development and progression (24) 24
dose-response relationship, drug (24) 24
maximum tolerated dose (24) 24
phosphorylation (24) 24
prognosis (24) 24
analysis (23) 23
antineoplastic agents - administration & dosage (23) 23
antitumor-activity (23) 23
carcinoma (23) 23
complications and side effects (23) 23
drug administration schedule (23) 23
mantle cell lymphoma (23) 23
protein kinase inhibitors - pharmacology (23) 23
cell proliferation - drug effects (22) 22
kinase inhibitor (22) 22
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2013, Volume 130, Issue 2, pp. 269 - 274
Journal Article
Journal Article
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 04/2010, Volume 40, Issue 8, pp. 732 - 738
Temsirolimus (CCI-779) is a novel inhibitor of the mammalian target of rapamycin. This Phase 1 study was aimed at investigating the maximum-tolerated dose,... 
Temsirolimus | Advanced solid tumor | Phase 1 study | CCI-779 | KINASE-ACTIVITY | DOSE LEVELS | advanced solid tumor | GLIOBLASTOMA-MULTIFORME | PTEN | II TRIAL | RENAL-CELL CARCINOMA | BREAST-CANCER | SINGLE-AGENT | INTERFERON-ALPHA | temsirolimus | ONCOLOGY | MTOR INHIBITOR | Diphenhydramine - administration & dosage | Lung Neoplasms - drug therapy | Disorders of Excessive Somnolence - chemically induced | Area Under Curve | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Diarrhea - chemically induced | Intestinal Perforation - chemically induced | Sirolimus - toxicity | Fever - chemically induced | Antineoplastic Agents - toxicity | Hyperglycemia - chemically induced | Colorectal Neoplasms - drug therapy | Adult | Antineoplastic Agents - pharmacokinetics | Hypophosphatemia - chemically induced | Carcinoma, Renal Cell - drug therapy | Neutropenia - chemically induced | Drug Eruptions - etiology | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Drug Administration Schedule | Treatment Outcome | Sirolimus - pharmacokinetics | Neoplasms - drug therapy | Hypertriglyceridemia - chemically induced | Maximum Tolerated Dose | Stomatitis - chemically induced | Aged | Infusions, Intravenous | Kidney Neoplasms - drug therapy | Anti-Allergic Agents - administration & dosage | Premedication | Index Medicus
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 4/2015, Volume 21, Issue 7, pp. 1558 - 1565
Journal Article
Cancer Cell International, ISSN 1475-2867, 03/2013, Volume 13, Issue 1, pp. 30 - 30
Background: Liver cancer is one of the most frequent cancers in the world. Targeted therapy of cancer with specific inhibitors is developing and has shown... 
Cell growth | Liver cancer cell | mTOR signaling | CCI-779 (temsirolimus) | MAMMALIAN TARGET | RAPAMYCIN | AZD8055 | PHASE-II | KINASE INHIBITOR | IN-VITRO | MODELS | ONCOLOGY | TOR | Antimitotic agents | Liver cancer | Care and treatment | Analysis | Cancer cells | Antineoplastic agents | Health aspects | Cancer | Proteins | Studies | Signal transduction | Flow cytometry | Phosphorylation | Liver | Cell cycle | Life sciences | Kinases | Cancer therapies
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 11/2010, Volume 16, Issue 22, pp. 5573 - 5580
Journal Article
Cancer, ISSN 0008-543X, 08/2011, Volume 117, Issue 15, pp. 3468 - 3475
BACKGROUND: The primary goal of this trial was to evaluate the confirmed response rate of temsirolimus (CCI‐779), a mammalian target of rapamycin in patients... 
toxicities | mammalian target of rapamycin | temsirolimus | soft tissue sarcoma
Journal Article
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 08/2019, Volume 516, Issue 3, pp. 726 - 732
Targeting the mammalian target of rapamycin (mTOR) is a promising strategy for cancer therapy. Temsirolimus, a FDA-approved anticancer drug with efficacy in... 
mTOR | Angiogenesis | Temsirolimus | Retinoblastoma | MANAGEMENT | BIOPHYSICS | CCI-779 | SAFETY | BIOCHEMISTRY & MOLECULAR BIOLOGY | GROWTH | COMBINATION | Drug approval | Analysis
Journal Article